Pigment Cell & Melanoma Research · 2017 · 212 citations · 17 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmunotherapy For Skin CancerNeoantigen ImmunologyT Cell Responses To TumorsTumor-associated AntigensAntitumor Immune ActivationCd8 Positive T CellsNeoantigen-specific T Cell ResponsesOncogenic Driver MutationsRag1 DeficiencySomatic Mutation AccumulationSomatic MutationsTumor Mutational Burden
Summary Human melanomas exhibit relatively high somatic mutation burden compared to other malignancies. These somatic mutations may produce neoantigens that are recognized by the immune system, leading to an antitumor response. By irradiating a parental mouse melanoma cell line carrying three driver mutations with UVB and expanding a single‐cell clone, we generated a mutagenized model that exhibits high somatic mutation burden. When inoculated at low cell numbers in immunocompetent C57 BL /6J mice, YUMMER 1.7 (Yale University Mouse Melanoma Exposed to Radiation) regresses after a brief period of growth. This regression phenotype is dependent on T cells as YUMMER 1.7 tumors grow significantly faster in immunodeficient Rag1 −/− mice and C57 BL /6J mice depleted of CD 4 and CD 8 T cells. Interestingly, regression can be overcome by injecting higher cell numbers of YUMMER 1.7, which results in tumors that grow without effective rejection. Mice that have previously rejected YUMMER 1.7 tumors develop immunity against higher doses of YUMMER 1.7 tumor challenge. In addition, escaping YUMMER 1.7 tumors are sensitive to anti‐ CTLA ‐4 and anti‐ PD ‐1 therapy, establishing a new model for the evaluation of immune checkpoint inhibition and antitumor immune responses.
17
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text
Medicine, Immunology, Oncology +17
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Genomic Classification of Cutaneous Melanoma
Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy et al. · Cell · 2015 · 3.2K citations · Full text
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 3K citations · Full text
Medicine, Cancer Biology, Oncology +17